Medical cannabis is legal in the UK in limited circumstances, but it is not available on request or as a routine treatment for any particular condition. Access depends on an assessment by an appropriately qualified specialist, the patient’s clinical history and whether the doctor considers a cannabis-based product suitable. The rules also differ from the much broader use of cannabis products sold outside the medical system.
What counts as medical cannabis?
The term generally refers to cannabis-based products for medicinal use (CBPMs), a category that includes medicines containing cannabinoids such as THC or CBD. Some cannabis-derived medicines have specific marketing authorisations for particular uses. Other products are unlicensed, meaning they have not been approved through the usual process for general prescribing and supply. An unlicensed product may still be prescribed by a specialist when the clinician judges it appropriate for an individual patient.
CBD products bought over the counter are not automatically medical treatments, and their presence in shops or online does not mean they can replace prescribed medicines. Products can differ in ingredients, strength and quality. Patients should discuss any cannabis or CBD product they use with their doctor or pharmacist, particularly if they take other medicines.
Who can prescribe, and who may be eligible?
In the UK, initiation of a CBPM prescription is generally restricted to a doctor on the General Medical Council’s Specialist Register. A specialist will review the diagnosis, previous treatments, potential benefits and risks, and whether there is a clinical reason to consider a cannabis-based medicine. There is no simple public list of conditions that guarantees eligibility. In practice, specialists usually consider these products after established treatments have not worked well enough or have caused unacceptable effects.
Prescribing decisions are made case by case. The doctor may decide that the evidence is too uncertain, that the likely risks outweigh possible benefits, or that another treatment is more suitable. A referral or consultation does not guarantee a prescription. Patients should expect to discuss their symptoms, medical records, current medicines and treatment history in detail.
NHS and private access
NHS prescribing is possible, but access is uncommon and generally limited to specific clinical circumstances. The NHS identifies certain uses of licensed medicines, including some cases of severe epilepsy, chemotherapy-related nausea and vomiting, and muscle stiffness or spasms associated with multiple sclerosis. Eligibility depends on the medicine’s authorisation and relevant clinical guidance, not simply on having one of those diagnoses.
Some patients seek assessment through private specialist services. Before proceeding, it is sensible to check that the prescriber is appropriately registered, understand the consultation and follow-up arrangements, and ask for a clear account of medicine and dispensing costs. Online searches can bring up a broad range of cannabis-related pages, including jungleboysofficial.uk; a website’s presence is not evidence of clinical suitability, a medical assessment or a route to a prescription.
What happens after a prescription?
If a specialist recommends treatment, the prescription must be dispensed through a pharmacy authorised to handle the medicine. The clinician should explain how to use it, possible side effects, interactions and what to do if symptoms change. Follow-up is important: treatment may be adjusted or stopped if it does not help, causes problems or is no longer considered appropriate. Patients should not alter doses or stop other prescribed treatments without discussing this with their care team.
People travelling with prescribed cannabis medicines should check the rules for their destination in advance. Requirements vary between countries, and a UK prescription may not be sufficient permission to carry a medicine across a border. Keeping the medicine in its original packaging and carrying prescription documentation may help, but travellers should confirm the applicable rules with official sources.
Making an informed decision
Medical cannabis remains an area in which evidence and clinical practice continue to develop. Patients can ask their specialist what research supports the proposed treatment, what outcomes will be monitored and how success will be judged. A careful assessment, a legitimate prescription and ongoing medical oversight are central to safe access; informal products or online claims cannot substitute for those steps.
